

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **ELLIOTT ET AL.**

APPLICATION NO.: **10/632,281**

: Examiner: Delacroix Muirhe, C.

FILING DATE: **AUGUST 1, 2003**

: Group Art Unit: 1614

TITLE: **THERAPEUTIC COMBINATIONS OF:
ERB B KINASE INHIBITORS AND
ANTINEOPLASTIC THERAPIES**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. §1.136(a)

Pursuant to the provisions of 37 C.F.R. §1.136(a), it is requested that the term for response to the Examiner's Action in this application, mailed on February 13, 2006, and having an original period for response of three (3) months, which expired on May 13, 2006, be extended by three (3) month(s), such that it expires on August 13, 2006 for the purpose of maintaining copendency for the filing of a continuation application.

Authorization is hereby provided to charge the amount of \$1,020.00, as stated under 37 C.F.R. §1.17, as well as any additional fees required, or to credit any overpayment to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Date: August 14, 2006

/Christian M. Smolizza/
Christian M. Smolizza
Attorney for Applicants
Reg. No. 46,319

Pfizer, Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-9094